DYNAMIC CHANGE IN PLASMA EGFR MUTATION DNA IN RESPONSE TO FIRST LINE THERAPY FOR ADVANCED STAGE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Mok, Tony [1 ]
Wu, Yi-Long [2 ]
Lee, Jin Soo [3 ]
Yu, Chong-Jen [4 ]
Sriuanpong, Virotw [5 ,6 ]
Wen, Wei [7 ]
Tsai, Julie [7 ]
Trueman, Matt [8 ]
Klughammer, Barbara [9 ]
Wu, Lin [7 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[3] Natl Canc Ctr, Res Inst & Hosp, Lung Canc Branch, Singapore, Singapore
[4] Natl Taiwan Univ Hosp, Zhongzheng, Taiwan
[5] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[6] Chulalongkorn Univ, Bangkok 10330, Thailand
[7] Roche Mol Syst Inc, Genom & Onocl Dept Res, Pleasanton, CA USA
[8] Roche Prod Ltd, Melbourne, Vic, Australia
[9] Hoffmann la Roche Ltd, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; mutation; plasma DNA; allele-specific PCR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O01.06
引用
收藏
页码：S133 / S134
页数：2
相关论文
共 50 条
  • [31] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Lopes, de Lima G.
    VALUE IN HEALTH, 2011, 14 (03) : A166 - A166
  • [32] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
    Shuhang Wang
    Xiaomei Su
    Hua Bai
    Jun Zhao
    Jianchun Duan
    Tongtong An
    Minglei Zhuo
    Zhijie Wang
    Meina Wu
    Zhenxiang Li
    Jian Zhu
    Jie Wang
    Journal of Hematology & Oncology, 8
  • [33] Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?
    Nooshin Hashemi-Sadraei
    Nathan A. Pennell
    Current Treatment Options in Oncology, 2012, 13 : 478 - 490
  • [34] Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?
    Hashemi-Sadraei, Nooshin
    Pennell, Nathan A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (04) : 478 - 490
  • [35] The therapy of locally advanced non-small cell lung cancer (NSCLC) in the elderly
    Schild, S. E.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S7 - S7
  • [36] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
    Wang, Shuhang
    Su, Xiaomei
    Bai, Hua
    Zhao, Jun
    Duan, Jianchun
    An, Tongtong
    Zhuo, Minglei
    Wang, Zhijie
    Wu, Meina
    Li, Zhenxiang
    Zhu, Jian
    Wang, Jie
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [37] EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctDNA) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Ai, X.
    Lin, Y.
    Zhang, J.
    Xie, C.
    Liu, A.
    Hu, X.
    Zhao, Q.
    Zang, Y.
    Rao, C.
    Hu, X.
    Chang, L.
    Li, Q.
    Guan, Y.
    Chen, R.
    Yi, X.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S412 - S413
  • [38] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [39] NOVEL EGFR TARGETED THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 81 - 81
  • [40] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
12345